Enantiomers of bronchodilating beta2-adrenoceptor agonists: is there a cause for concern?
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Summary
This summary is machine-generated.The (R)-enantiomer of beta2-agonists provides therapeutic effects, while the (S)-enantiomer is largely inactive. Current research suggests (S)-enantiomers may induce airway hyperreactivity, but clinical evidence remains inconclusive.
Area Of Science
- Pharmacology
- Respiratory Medicine
- Drug Development
Background
- Bronchodilating beta2-adrenoceptor agonists are adrenaline derivatives used clinically as racemates.
- Pharmacological data predominantly uses racemic mixtures, with limited studies on individual enantiomers.
- The (R)-enantiomer is recognized for established beta2-agonist effects; the (S)-enantiomer is considered virtually inactive.
Purpose Of The Study
- To investigate the role of individual enantiomers of beta2-adrenoceptor agonists, particularly concerning airway hyperreactivity.
- To elucidate the mechanism of action for observed effects of (S)-enantiomers in preclinical models.
- To evaluate the clinical significance of airway hyperreactivity induced by (S)-enantiomers.
Main Methods
- Review of existing pharmacological and clinical studies on racemic and individual enantiomers of beta2-agonists.
- Analysis of in vitro experiments investigating potential mechanisms, including calcium mobilization.
- Examination of clinical trials focusing on salbutamol enantiomers and their effects.
Main Results
- Preclinical studies in guinea pigs suggest (S)-enantiomers may induce airway hyperreactivity.
- In vitro studies indicate (S)-salbutamol might mobilize intracellular calcium via a cholinergic pathway, requiring further research.
- Clinical studies confirm that the therapeutic effects of salbutamol reside in the (R)-enantiomer.
- Current clinical data does not convincingly demonstrate significant airway hyperreactivity from (S)-salbutamol exposure.
Conclusions
- The therapeutic benefits of beta2-agonists are attributed to the (R)-enantiomer.
- The role of the (S)-enantiomer in causing clinically significant airway hyperreactivity requires further investigation.
- Additional research is necessary to definitively resolve the clinical implications of (S)-enantiomer exposure.
View abstract on PubMed
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...